LP002
- Generic Name
- LP002
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT04756934
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
- Conditions
- Digestive System Neoplasms
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT04755543
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital & Insititute, Zhengzhou, Henan, China
🇨🇳Liaoning Cancer Hospital & Insititute, Shenyang, Liaoning, China
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT04740021
- Locations
- 🇨🇳
Affiliated Hospital Of Jiangnan University, Wuxi, Jiangsu, China
🇨🇳The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT04600947
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.